nam/aidsmap, 28 October 2015
While epidemiologists and public health experts are excited by the potential of new hepatitis C drugs to limit onward transmission of the virus among people who inject drugs, the strategies ignore profound barriers to drug users engaging with healthcare and their broader needs.
For ‘treatment as prevention’ to be ethical and acceptable to people who inject drugs, enabling treatment and policy environments need to be created.
Read more here